Boehringer Ingelheim has ended a decade of industrywide failures in idiopathic pulmonary fibrosis (IPF) by reporting a phase 3 win for a potentially first-in-class candidate and outlining plans to ...

Hung jury in latest Zantac cancer trial in Chicago Boehringer Ingelheim only defendant after settlements with GSK, Pfizer FDA pulled Zantac in 2020 over NDMA carcinogen concerns Sept 18 (Reuters ...

By Noah Weiland and Rebecca Robbins Hikma said it had reduced the cash portion of the offer as Boehringer Ingelheim’s generic drugs business in the U.S. had lower-than-expected sales.

Boehringer Ingelheim has moved one of its top pipeline ... The first patient has already been enrolled into its FIBRONEER phase 3 programme for BI 1015550, which already has a breakthrough ...

Boehringer Ingelheim’s weight-loss drug candidate ... dysfunction-associated steatotic liver disease (MASLD), which in turn has been rebranded from non-alcoholic fatty liver disease (NAFLD).

1-3 Vision loss associated ... which in turn can have an impact on mental health, leading to depression, fear and anxiety.4 About Boehringer Ingelheim Boehringer Ingelheim is working on ...

Phase Ib met its primary endpoint, demonstrating a meaningful objective response rate (ORR) of 66.7%, as assessed by blinded ...

The heritage of Boehringer Ingelheim in developing ... leading to widening of the airways, which, in turn, improves expiratory flow 3. Since obstruction of the airways and associated symptoms ...

They’re still a little expensive compared to their fixed-bed cousins though, so if you hanker for a Creality CR30 but only have the cash for an Ender 3, [Michael Sgroi] may have the project for you.

3 "These new data could represent positive ... Paola Casarosa, Board of Managing Directors, Head of Innovation Unit at Boehringer Ingelheim, said: “Zongertinib’s efficacy and tolerability ...

At the IASLC 2024 World Conference on Lung Cancer (WCLC) Boehringer Ingelheim will present encouraging ... on Saturday, September 7, from 3:45PM to 4:45PM PDT (Location: 30DE).